TITLE

aaiPharma to acquire rival Cima Labs

PUB. DATE
September 2003
SOURCE
PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p19
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on the intention of aaiPharma Inc. to acquire Cima Labs Inc. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the pharmaceutical biotechnology industry.
ACCESSION #
13861594

 

Related Articles

  • aaiPharma acquires unique Darvocet line extension.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p18 

    Reports on aaiPharma Inc.'s acquisition of a unique Darvocet line extension from Athlon Pharmaceuticals. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the development of Darvocet line extension. Terms under the acquisition; Benefits of the...

  • CIMA/aaiPharma Tie the Pharmaceutical Knot.  // High Yield Report;8/11/2003, Vol. 14 Issue 32, p1 

    Reports on the proposed merger between U.S.-based pharmaceutical companies aaiPharma and CIMA. Impact of the proposed merger on the financial conditions of the drug manufacturing industry; Estimated capital of the merged companies; Financial standings of the two pharmaceutical companies.

  • Pharma says acquisition is the right prescription. Speizer, Irwin // Business North Carolina;Oct2003, Vol. 23 Issue 10, p22 

    Reports on the merger of drug company aaiPharma Inc. with Cima Labs Inc. in 2003. Basis of the consolidation; Impact of the merger on the companies' stock performance; Changes after the merger.

  • Evotec and Nuvios team up to tackle osteoporosis.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p14 

    Reports on the collaboration of Evotec with Nuvious for the screening of novel small molecule compounds for potential new drugs targeting osteoporosis. Terms under the agreement; Benefits of the deal for both companies; Significance of the agreement for the pharmaceutical biotechnology industry.

  • UCB set to acquire Celltech for £1.5bn.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p18 

    Reports on the acquisition of Celltech Pharmaceuticals by UCB Group Ltd. Terms under the agreement; Benefits of the deal for both companies; Significance of the agreement for the pharmaceutical biotechnology industry.

  • Entropin in ENT-103 research collaboration.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p17 

    Reports on the research agreement of Entropin Inc. with a specialty pharmaceutical company that owns U.S. and international patent and other proprietary rights to technologies that enhance or facilitate the absorption of drugs across biological membranes. Terms under the agreement; Benefits of...

  • Yamanouchi and GSK enter co-promotion agreement for Vesicare in the US.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p23 

    Reports on the agreement between Yamanouchi Pharmaceutical Co. Ltd. and GlaxoSmithKline PLC for the promotion of Vesicare, an investigational compound for overactive bladder. Terms under the agreement; Benefits of the deal for both companies; Significance of the agreement for the pharmaceutical...

  • Ovation acquires Mebaral, Chemet, and Winstrol From Sanofi-Synthelabo.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p25 

    Reports on the acquisition of the exclusive U.S. rights of three Sanofi-Synthelabo SA by Ovation Pharmaceuticals Inc. Terms under the acquisition; Benefits of the deal for both companies; Significance of the agreement for the development of products.

  • Novartis moves to acquire NeuTec Pharma. Mirasol, Feliza // Chemical Market Reporter;6/12/2006, Vol. 269 Issue 23, p7 

    The article reports on the interest of Novartis AG in acquiring biopharmaceutical firm NeuTec Pharma PLC. With the acquisition, the company would gain entry into the fast growing market for anti–infectives. The proposed acquisition of NeuTec exemplifies the commitment of Novartis to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics